ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

Chen Hua Jun; Mok Tony S; Chen Zhi Hong; Guo Ai Lin; Zhang Xu Chao; Su Jian; Wu Yi Long*广东省人民医院; 香港中文大学
Pathology Oncology Research2009-12DOI: 10.1007/s12253-009-9167-8
30被引5阅读
引用收藏
分享

摘要

To investigate the clinicopathologic and molecular features of the T790M mutation and c-MET amplification in a cohort of Chinese non-small cell lung cancer (NSCLC) patients resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR TKI-resistant NSCLC patients (n = 29) and corresponding tumor specimens, and 53 samples of postoperative TKI-naive NSCLC patients were collected. EGFR exon 19, 20, and 21 mutations were analyzed. And c-MET gene copy number was determined. The EGFR T790M mutation in exon 20 was not detected in the population of 53 TKI-naive patients, but found in 48.3% (14/29) of the enrolled TKI-resistant patients. c-MET was amplified in 3.8% (2/53) of the TKI-naive NSCLC patients and highly amplified in 17.2% (5/29) of the cohort. Most of T790M mutations were frequently associated with non-smoker, adenocarcinoma and EGFR activating mutations. Three male patients with T790M mutation occurred with wild-type EGFR, and were resistant to the treatments following TKI resistance. Features of c-MET amplification in TKI-naive patients were indistinguishable from TKI-resistant patients. In the group of wild-type EGFR, patients with T790M mutation had median progression free survival (PFS) and overall survival (OS) as 9.6 months and 12.6 months, respectively; whereas the median PFS and OS of c-MET amplified patients was 4.1 months and 8.0 months, respectively. These results suggest that EGFR T790M mutation and c-MET amplification can occur in TKI-resistant NSCLC with wild-type EGFR, and these genetic defects might be related to different survival outcome. c-MET amplification in TKI-naive or -resistant patients might share similarities in clinicopathologic features.

学科与关键词

关键词
c-METEpidermal growth factor receptorNon-small cell lung cancer, ResistanceT790M
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Pathology Oncology Research
发表日期
2009-12
卷期
第 15 卷, 第 4 期
页码
651-658
DOI
10.1007/s12253-009-9167-8
语言
ENGLISH
成果收录
SCI
资助标注
National Natural Science Foundation of China [30772531]; Foundation of Guangdong Science and Technology Department [2007A032000002]; Chinese Lung Cancer Research Foundation

作者

  • C

    Chen Hua Jun (第一作者)

    guangdong gen hosp

  • M

    Mok Tony S

    chinese univ hong kong

查看全部 7 位作者收起作者
  • C

    Chen Zhi Hong

    guangdong gen hosp

  • G

    Guo Ai Lin

  • Z

    Zhang Xu Chao

  • S

    Su Jian

    guangdong gen hosp

  • W

    Wu Yi Long (通讯)

    guangdong gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417